We have not found any studies on the effects of targeted therapies, including biologics, on the production of anti-CS or anti-TOPO-F4 nAAbs in RA, AS, or any other autoimmune-inflammatory rheumatic diseases. Here, CS is linked to rheumatoid arthritis.